高脂質血症患者に対するプロブコールの効果

抄録

Probucol, newly developed hypocholesterolemic agent, was given to 130 patients (47 males and 83 females) whose serum cholesterol values were mostly 230mg% or higher with an exception of 9 patients whose values were less than that. The administration was continued for 16 weeks and then placebo was given for 4 weeks more. The results are as follows.
The serum cholesterol level significantly decreased already at the fourth week of the Probucol administration stage. The overall rate of decrease at the end of the sixteenth week was approximately 17%. Though the level slightly increased by giving placebo for succeeding 4 weeks, the final value still showed a statistically significant decrease from the initial level.
With reference to a triglyceride level, similar results were obtained.
Decrease in HDL-C level was around 20 during 16 weeks and, even after administration of placebo for succeeding 4 weeks, the decrease was kept still in 15% showing a significant difference from the initial HDL-C level.
Concerning atherogenic index (TC-HDL-C/HDL-C), there was no significant change.
Difference in the effects of Probucol against the patients with hyperlipemia and those with hypertension, diabetes mellitus and ischemic heart diseases was then tested but there was found no significant difference so far as changes in serum cholesterol, HDL-C and AT were concerned.
Patients with hypertension were divided into two groups—one administered with thiazide agents and another with non-thiazide ones—and the tests were conducted. As a result, there was a slight inclination that AI in the latter group was rather higher though there was no significant difference as compared with that in the former group.
With reference to diabetes mellitus, the patients were divided into three groups—the first group being treated by dieting, the second one with sulfonylurea, and the third with insulin. There was, however, no significant difference among those groups.
As to side effects, 5 cases showed nausea, epigastrial distress, etc. which corresponded to 3.8 of the total patients tested.